|Bid||3.5000 x 1000|
|Ask||3.5500 x 1000|
|Day's Range||3.5100 - 3.6400|
|52 Week Range||1.9800 - 4.5000|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14). Fast Track designation provides an opportunity for more frequent interactions with the FDA review team throughout the development program. Under Fast Track designation, a Biologic License Application (BLA) for CERC-002 is eligible for both rolling submission and priority review.1 In March, the company announced final efficacy data from the Phase 2 trial evaluating CERC-002 for COVID-19 associated pneumonia and acute respiratory distress syndrome (ARDS). At both the 28-day and the 60-day final timepoints, an approximately 50% trend in mortality reduction (22.5% vs. 10.8%) was observed. Price Action: CERC shares are up 15% at $2.92 during the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaPandemic Hits Perrigo Q1 Top And BottomlineBiogen, Capsigen Ink .3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.